Support and Resistance Basics

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

TOMDF


Top 10 Correlated ETFs

TOMDF


Top 10 Correlated Stocks

TOMDF


In the News

10:05 13 Aug 2022 TOMDF

Todos Medical says 3CL Pharma subsidiary completes trial design for Tollovid Long COVID clinical study in adults

Todos Medical Ltd. (OTCQB:TOMDF) said its majority-owned subsidiary 3CL Pharma Ltd has finished plans for a proposed safety and efficacy clinical trial for its 3CL protease inhibitor immune support dietary supplement Tollovid in patients with Long COVID.

10:04 13 Aug 2022 TOMDF

Todos Medical completes trial design for Tollovid Long COVID clinical study in adults

Todos Medical Ltd. (OTCQB:TOMDF) said its majority-owned subsidiary 3CL Pharma Ltd has finished plans for a proposed safety and efficacy clinical trial for its 3CL protease inhibitor immune support dietary supplement Tollovid in patients with Long COVID.

11:04 13 Aug 2022 TOMDF

Todos Medical says Provista Diagnostics lab finishes validation of Wound and Respiratory Pathogen panels; plans to add monkeypox testing

Todos Medical Ltd announced that its CLIA/CAP-certified laboratory Provista Diagnostics has completed validation of its PCR-based Wound and Respiratory Pathogen panels.  The Wound Panel (WP) is a 31-pathogen multiplexed PCR panel, including antibiotic resistance, taken from swab samples of a wound or lesion.

09:00 13 Aug 2022 TOMDF

Todos Medical says Provista Diagnostics to provide PCR-based monkeypox testing for clients in New Jersey

Todos Medical Ltd. (OTCQB:TOMDF) said its clinical testing laboratory Provista Diagnostics has entered into two contracts to provide PCR-based monkeypox testing.

03:39 13 Aug 2022 TOMDF

Todos Medical wins first lab services contract for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics

Todos Medical Ltd revealed that the first commercial patient samples have been received for its Long COVID Panel biomarker partnership between its CLIA/CAP certified lab Provista Diagnostics and Amerimmune Diagnostics, which also has a CLIA/CAP certified lab with immune diagnostics expertise. The medical diagnostics company said the patient samples were requisitioned by Long COVID clinic Real Time Health Monitoring (RTHM).

09:27 13 Aug 2022 TOMDF

Todos Medical poised to branch into MonkeyPox testing as Provista Diagnostics begins validation plan

Todos Medical Ltd. (OTCQB:TOMDF) is set to branch into the world of MonkeyPox testing through its subsidiary Provista Diagnostics Inc, which has started a validation plan for PCR-based testing.

10:59 13 Aug 2022 TOMDF

Todos Medical says new study highlights case for use of dietary supplement product Tollovid

Todos Medical Ltd has said that its majority-owned joint venture 3CL Pharma Ltd has once again highlighted the case for its oral dietary supplement Tollovid, pointing to a pre-print in ResearchGate of a study that used the product. The study, entitled 'Tollovid as a Rescue Agent for Paxlovid Rebound in Acute COVID-19', outlined the case, overseen by Dr Lee Morgentaler in concert with Andrew A.

09:02 13 Aug 2022 TOMDF

Todos Medical partners with Amerimmune Diagnostics on long-COVID biomarker panel

Todos Medical Ltd. (OTCQB:TOMDF) announced that its CLIA/CAP certified clinical laboratory Provista Diagnostics has entered into an agreement with Amerimmune Diagnostics, a CLIA/CAP certified laboratory with expertise in immune diagnostics and a leader in the field of clinical immunology and immune assessment of acute and long-COVID.

11:54 13 Aug 2022 TOMDF

Todos Medical and 3CL Pharma hail return to better health in long COVID case through use of Tollovid

Todos Medical Ltd reported positive results in the use of the medication Paxlovid and dietary supplement Tollovid in the treatment of a patient with long COVID. Comprehensive medical diagnostics and related solutions company Todos Medical announced its majority-owned joint venture 3CL Pharma Ltd is reporting the advance copy of a case study number eight titled "A Case Review: Effects of 3CL Protease Inhibitors Paxlovid and Tollovid in a Patient with Chronic Long COVID" by Dr Lee Morgentaler and Andrew Blumenthal.

09:23 13 Aug 2022 TOMDF

Todos Medical plans open label extension of Phase 2 trial of Tollovir in hospitalized Covid patients after encouraging biomarker data

Todos Medical Ltd. (OTCQB:TOMDF) has announced biomarker data from its majority-owned joint venture 3CL Pharma Ltd's Phase 2 clinical trial of Tollovir in hospitalized COVID-19 patients, along with plans to expand its patient sample size.

Financial details

Company Rating
Neutral
Market Cap
25.53M
Income
-14.58M
Revenue
9.4M
Book val./share
-0.03
Cash/share
0
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
21 Apr 2021
P/E
-1.61
Forward P/E
-
PEG
0.18
P/S
2.49
P/B
-0.93
P/C
-
P/FCF
9.32
Quick Ratio
0.23
Current Ratio
0.37
Debt / Equity
-0
LT Debt / Equity
-
-
-
EPS (TTM)
-0.01
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-50.66%
EPS Q/Q
-
-
-
-
-
SMA20
200%
SMA50
200%
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-106%
ROE
85%
ROC
0.03%
Gross Margin
37%
Oper. Margin
1%
Profit Margin
-155%
Payout
-
Shs Outstand
1.19B
Shs Float
965.85M
-
-
-
-
Target Price
-
52W Range
0.01-0.105
52W High
-
52W Low
-
RSI
74.49
Rel Volume
3.65
Avg Volume
4.58M
Volume
16.74M
Perf Week
65.79%
Perf Month
142.31%
Perf Quarter
-1.56%
Perf Half Y
-23.17%
-
-
-
-
Beta
-1.2196
-
-
Volatility
0%, 0.01%
Prev Close
-1.56%
Price
0.0315
Change
-10%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0000.020.05
Net income per share
-0.04-0.01-0.13-0.110
Operating cash flow per share
-0.01-0.010-0.010
Free cash flow per share
-0.01-0.020-0.020
Cash per share
0.010000
Book value per share
-0.02-0.02-0.07-0.04-0.09
Tangible book value per share
-0.02-0.02-0.07-0.04-0.03
Share holders equity per share
-0.02-0.02-0.07-0.04-0.09
Interest debt per share
00.010.050.060
Market cap
58.3M9.92M2.76M13.74M11.92M
Enterprise value
57.62M10.49M6.6M24.24M11.87M
P/E ratio
-21.79-21.69-0.23-0.460
Price to sales ratio
0002.640.97
POCF ratio
-64.46-9.390-5.370
PFCF ratio
-64.21-9.260-2.7365.15
P/B Ratio
-43.52-8.16-0.44-1.25-0.49
PTB ratio
-43.52-8.16-0.44-1.25-0.49
EV to sales
0004.660.97
Enterprise value over EBITDA
-43.86-4.51-0.75-0.94-17.57
EV to operating cash flow
-63.71-9.930-9.480
EV to free cash flow
-63.45-9.790-4.8164.89
Earnings yield
-0.05-0.05-4.28-2.170
Free cash flow yield
-0.02-0.110-0.370.02
Debt to equity
00-0.6-0.77-0.01
Debt to assets
2.647.1169.742.831
Net debt to EBITDA
0.52-0.24-0.43-0.410.07
Current ratio
2.910.090.020.30.53
Interest coverage
00-3.67-3.720
Income quality
0.342.3100.090
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0001.110.77
Research and developement to revenue
0001.89-0.07
Intangibles to total assets
00000.51
Capex to operating cash flow
00.0100.970
Capex to revenue
000-0.480.01
Capex to depreciation
-0.15-0.6-0.04-25.830
Stock based compensation to revenue
0000.50
Graham number
0.130.050.440.330
ROIC
-2.341.382.396.92-0.11
Return on tangible assets
-3.28-2.3-129.97-4.950
Graham Net
-0.02-0.02-0.07-0.06-0.05
Working capital
468.26K-1.09M-1.54M-5.62M-4.24M
Tangible asset value
0000-7.72M
Net current asset value
-1.44M-1.31M-6.31M-14.57M-10.4M
Invested capital
0-0.52-0.62-1.04-0.01
Average receivables
000378K1.45M
Average payables
0901.59K1.03M1.64M1.96M
Average inventory
000536K1.07M
Days sales outstanding
00026.575.21
Days payables outstanding
000156.78105.87
Days of inventory on hand
00051.2474.56
Receivables turnover
00013.784.85
Payables turnover
0002.333.45
Inventory turnover
0007.124.9
ROE
20.381.892.70
Capex per share
000-0.010

Quarterly Fundamentals Overview

Last date of statement is 2022-03-31 for Q1

Metric History 2021-03-312021-06-302021-09-302021-12-31 2022-03-31
Revenue per share
0.01000.010
Net income per share
-0.040.01-0.010-0.01
Operating cash flow per share
-0.010-0.0100
Free cash flow per share
-0.01-0.01-0.010.020
Cash per share
00000
Book value per share
-0.04-0.02-0.01-0.03-0.03
Tangible book value per share
-0.04-0.03-0.01-0.01-0.01
Share holders equity per share
-0.04-0.02-0.01-0.03-0.03
Interest debt per share
0.050.04000
Market cap
24.52M20.16M29.48M42.74M14.74M
Enterprise value
45.3M40.24M29.4M42.69M14.78M
P/E ratio
-0.351.49-0.710-0.49
Price to sales ratio
4.8711.6429.199.596.7
POCF ratio
-7.71-7.17-4.540-11.67
PFCF ratio
-6.39-6.9-4.012.99-9.78
P/B Ratio
-1.26-2.24-2.81-1.77-0.59
PTB ratio
-1.26-2.24-2.81-1.77-0.59
EV to sales
923.2329.119.586.72
Enterprise value over EBITDA
-3.4211.21-2.938.03-2
EV to operating cash flow
-14.25-14.32-4.530-11.7
EV to free cash flow
-11.8-13.77-42.99-9.81
Earnings yield
-0.720.17-0.350-0.51
Free cash flow yield
-0.16-0.14-0.250.33-0.1
Debt to equity
-0.96-1.96-0.01-0.010
Debt to assets
4.041.52111
Net debt to EBITDA
-1.575.590.01-0.01-0.01
Current ratio
0.340.490.520.530.37
Interest coverage
-0.440000
Income quality
0.18-0.830.6300.17
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.580.95-1.851.51.58
Research and developement to revenue
0.140.14-0.16-0.36-0.2
Intangibles to total assets
00.540.540.510.51
Capex to operating cash flow
0.210.040.1300.19
Capex to revenue
-0.13-0.06-0.840.41-0.11
Capex to depreciation
-4.22-0.56-2.40-1.24
Stock based compensation to revenue
0.050.090.4600.71
Graham number
0.190.050.0700.09
ROIC
4.38-0.18-0.280.86-0.37
Return on tangible assets
-2.740.42-1.310-1.12
Graham Net
-0.05-0.04-0.02-0.02-0.01
Working capital
-4.51M-4.17M-3.92M-4.24M-6.78M
Tangible asset value
0-18.26M-9.26M-7.72M-6.94M
Net current asset value
-23.55M-22.33M-12.89M-10.4M-9.68M
Invested capital
-1.08-2.27-0.01-0.010
Average receivables
1.47M2.16M02.52M2.45M
Average payables
1.81M1.68M1.72M2.28M2.79M
Average inventory
1.6M1.65M1.75M1.6M1.62M
Days sales outstanding
7.593.12050.8997.41
Days payables outstanding
37.45107.15100.8777.13225.44
Days of inventory on hand
44.23167.97164.354.32112.21
Receivables turnover
12.010.9701.770.92
Payables turnover
2.40.840.891.170.4
Inventory turnover
2.030.540.551.660.8
ROE
0.9-0.380.9900.3
Capex per share
00000

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap